What is the recommended treatment for intraventricular hemorrhage?

Treatment for Intraventricular Hemorrhage

For intraventricular hemorrhage with hydrocephalus causing decreased consciousness, place an external ventricular drain (EVD) immediately, and add intraventricular fibrinolysis with alteplase or urokinase to improve survival. 1, 2

Primary Management Algorithm

Step 1: Assess for Hydrocephalus and Clinical Severity

• GCS ≤13 with moderate-to-large IVH (Graeb score ≥7) indicates need for intervention 2
• Decreased level of consciousness with hydrocephalus is the key trigger for EVD placement 1, 3, 1

Step 2: External Ventricular Drainage (Class I Recommendation)

EVD placement is the cornerstone of IVH management and should be performed urgently in patients with:

• Clinical hydrocephalus causing decreased consciousness 3, 4
• Obstructive hydrocephalus from blood blocking CSF pathways 2

EVD alone improves survival compared to conservative treatment, particularly in patients with ICH volume >11 mL and severe IVH 2

Step 3: Add Intraventricular Fibrinolysis (Class I for Mortality Reduction)

Administer alteplase or urokinase through the EVD when:

• IVH involves ≥30% of lateral ventricle volume and/or involves 3rd or 4th ventricle 5
• Small-to-moderate ICH (<30 mL) with obstructive IVH 2
• IVH obstructing the third or fourth ventricle 2

Dosing regimen: Alteplase 1-4 mg every 8-12 hours through the EVD 4

Evidence for fibrinolysis:

• Reduces mortality from 40.9% to 22.4% 6
• Decreases catheter occlusion from 37.3% to 10.6% 6
• Accelerates clot clearance 4, 7
• Does NOT increase symptomatic hemorrhage risk 2

Step 4: ICP Monitoring (Class IIb)

Consider ICP monitoring if:

• GCS ≤8 3, 4
• Clinical transtentorial herniation 3
• Maintain cerebral perfusion pressure 50-70 mmHg 3, 4

Critical Caveats

Before starting fibrinolysis: Rule out or secure any bleeding source (e.g., unsecured aneurysm) 5. In spontaneous IVH without parenchymal hemorrhage, catheter angiography is recommended to exclude vascular anomalies 1.

Anticoagulation reversal: If IVH occurs in anticoagulated patients, immediately reverse:

• Warfarin: 4-factor prothrombin complex concentrate (PCC) over fresh frozen plasma, plus IV vitamin K 1, 3, 1
• Dabigatran: Idarucizumab 1
• Factor Xa inhibitors: Andexanet alpha or 4F-PCC if unavailable 1
• Heparin: Protamine sulfate 1, 3

Blood pressure control: Target systolic BP <140 mmHg (avoid <110 mmHg) within 6 hours to prevent hematoma expansion 1, 8

Functional Outcomes

The evidence shows definitive mortality reduction with EVD plus fibrinolysis 2, 6, but functional outcome benefit remains uncertain (Class IIb) 2. The CLEAR III trial showed mortality benefit but did not demonstrate improved functional outcomes at 180 days 2. However, meta-analyses suggest improved good functional outcomes (47.2% vs 38.3%) 6.

Shunt dependency: Related to initial blood volume in ventricles, not affected by fibrinolysis 6. Consider controlled lumbar drainage to potentially reduce permanent hydrocephalus 7.

What NOT to Do

• Do NOT use corticosteroids for elevated ICP in ICH (Class III) 4
• Do NOT delay EVD placement in patients with decreased consciousness and hydrocephalus—this is time-sensitive 1, 3
• Do NOT use EVD alone when fibrinolysis is indicated—you're missing a proven mortality benefit 2, 6